Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.

Conclusions: IGFBP-2 may have a role in altering metabolic risk in schizophrenic patients using SGAs. Longitudinal studies are required to evaluate whether IGFBP-2 can predict the development of a hyperTG waist phenotype in this population. PMID: 32552257 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32552257?dopt=Abstract

Source: The World Journal of Biological Psychiatry - June 16, 2020 Category: Psychiatry Authors: Nolin MA, Demers MF, Rauzier C, Bouchard RH, Cadrin C, Després JP, Roy MA, Alméras N, Picard F Tags: World J Biol Psychiatry Source Type: research